Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma

Inclusion Criteria: 1. 18-70 years old on the day the patients voluntary to participate in the study and signing in ICF. 2. Histological or clinical diagnosis of HCC. 3. BCLC stage C patients ineligible for surgical resection or liver transplantation. 4. No prior systemic therapy for HCC (including immunotherapy). 5. Have at least one uni-dimensional lesion measurable by CT scan or magnetic resonance imaging per mRECIST. 6. Child-Pugh A-B7. 7. ECOG PS 0-1. 8. Adequate hematological function (absolute neutrophil count ≥ 1.5 X 109/L, platelets count≥50 X109/L, and hemoglobin ≥85 g/L); Adequate hepatic function (both AST and ALT ≤ 3 ULN, serum total bilirubin ≤ 34.2 umol/L or 2mg/dl, serum albumin ≥ 29g/L); Adequate renal function (eGFR \> 30 ml/min/1.73 m2) 9. For patients with HBV or HCV infection, HBV DNA less than 500 IU/ml (2500 copies/ml) or HCV RNA detectable. 10. life expectancy of more than 3 months. 11. Patients must be able to understand and willing to sign a written informed consent document. 12. Patients suitable for TACE therapy assessed by investigators. Exclusion Criteria: 1. Tumor thrombus involving main trunk of portal vein or inferior vena cava. 2. Prior local-regional therapy before beginning of study treatment (surgery or ablation allowed at BCLC stage 0-B) or radiotherapy on liver cancer. 3. Disease history of grade 2 or more hepatic encephalopathy. 4. Extrahepatic metastasis on baseline imaging. 5. HIV infection or syphilis. 6. Prior therapies with any anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-CTLA-4 agents. 7. Tumor diffuse.